34260-72-5

Usage

Uses

Used in Pharmaceutical Industry:
L-Phe(3-OH)-OMe.Hcl is used as a key intermediate in the synthesis of Fmoc-L-phenylalanine derivatives, specifically for the preparation of tert-butoxy substituted Fmoc-L-phenylalanine. This L-tyrosine analog is crucial for the development of novel pharmaceutical compounds, potentially leading to advancements in drug discovery and therapeutic applications.
In the context of the provided materials, L-Phe(3-OH)-OMe.Hcl plays a significant role in the creation of specialized amino acid analogs, which can be utilized in various research and development processes within the pharmaceutical sector. Its unique chemical properties make it a versatile building block for the synthesis of innovative drug candidates.

Upstream product

• 67-56-1 methanol 
• 72683-77-3 N-formyl-L-m-hydroxyphenylalanine 
• 587-33-7 m-tyrosine 
• 775-06-4 D/L-3-hydroxy-phenylalanine 

Downstream Products

• 1031845-64-3 (S)-3-Benzyloxycarbonylamino-N-[(S)-2-(3-hydroxy-phenyl)-1-methoxycarbonyl-ethyl]-succinamic acid benzyl ester 
• 371111-65-8 10-cyclohexyl-8,11-dioxo-2-oxa-9,12-diazabicyclo[13.3.1]nonadeca-1⁽¹⁹⁾,15,17-triene-13-carboxylic acid 
• 371111-64-7 10-cyclohexyl-8,11-dioxo-2-oxa-9,12-diazabicyclo[13.3.1]nonadeca-1⁽¹⁹⁾,15,17-triene-13-carboxylic acid methyl ester 
• 371111-60-3 methyl 11(S)-cyclohexyl-9,12-dioxo-2-oxa-10,13-diazabicyclo[14.3.1]eicosa-1⁽²⁰⁾,16,18-triene-14(S)-carboxylate 
• 371111-61-4 11(S)-cyclohexyl-9,12-dioxo-2-oxa-10,13-diazabicyclo[14.3.1]eicosa-1⁽²⁰⁾,16,18-triene-14(S)-carboxylic acid 
• 371111-58-9 N-6-heptenoyl-(S)-cyclohexylglycine-(S)-m-tyrosine methyl ester 
• 371111-63-6 2-[2-cyclohexyl-2-(5-hydroxypentanoylamino)acetylamino]-3-(3-hydroxyphenyl)propionic acid methyl ester 
• 371111-59-0 N-7-hydroxyheptanoyl-(S)-cyclohexylglycine-(S)-m-tyrosine methyl ester 
• 371110-98-4 (S)-(2-{3-[((11S,14S)-11-Cyclohexyl-9,12-dioxo-2-oxa-10,13-diaza-bicyclo[14.3.1]icosa-1⁽¹⁹⁾,16⁽²⁰⁾,17-triene-14-carbonyl)-amino]-2-oxo-hexanoylamino}-acetylamino)-phenyl-acetic acid 
• 371111-66-9 (S)-(2-{3-[((10S,13S)-10-Cyclohexyl-8,11-dioxo-2-oxa-9,12-diaza-bicyclo[13.3.1]nonadeca-1⁽¹⁸⁾,15⁽¹⁹⁾,16-triene-13-carbonyl)-amino]-2-hydroxy-hexanoylamino}-acetylamino)-phenyl-acetic acid tert-butyl ester 
• 371110-99-5 (S)-(2-{3-[((10S,13S)-10-Cyclohexyl-8,11-dioxo-2-oxa-9,12-diaza-bicyclo[13.3.1]nonadeca-1⁽¹⁸⁾,15⁽¹⁹⁾,16-triene-13-carbonyl)-amino]-2-oxo-hexanoylamino}-acetylamino)-phenyl-acetic acid tert-butyl ester 
• 371111-62-5 (S)-(2-{3-[((11S,14S)-11-Cyclohexyl-9,12-dioxo-2-oxa-10,13-diaza-bicyclo[14.3.1]icosa-1⁽¹⁹⁾,16⁽²⁰⁾,17-triene-14-carbonyl)-amino]-2-hydroxy-hexanoylamino}-acetylamino)-phenyl-acetic acid tert-butyl ester 
• 371110-97-3 (S)-(2-{3-[((11S,14S)-11-Cyclohexyl-9,12-dioxo-2-oxa-10,13-diaza-bicyclo[14.3.1]icosa-1⁽¹⁹⁾,16⁽²⁰⁾,17-triene-14-carbonyl)-amino]-2-oxo-hexanoylamino}-acetylamino)-phenyl-acetic acid tert-butyl ester 
• 900800-02-4 2S-tert-butoxycarbonylamino-3-(3-hydroxyphenyl)propionic acid methyl ester 

Relevant academic research and scientific papers

SMALL MOLECULE MODULATORS OF IL-17

The present invention relates to a compound according to formula I and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to, to said compounds for use in therapy, to pharmaceutical compositions comprising said

SAR study of tyrosine-chlorambucil hybrid regioisomers; Synthesis and biological evaluation against breast cancer cell lines

Amino acids were transformed and coupled to chlorambucil, a well-known chemotherapeutic agent, in an attempt to create new anticancer drugs with selectivity for breast cancer cells. Among the amino acids available, tyrosine was selected to act as an estrogenic ligand. It is hypothesized that tyrosine, which shows some structural similitude with estradiol, could possibly mimic the natural hormone and, subsequently, bind to the estrogen receptor. In this exploratory study, several tyrosine-drug conjugates have been designed. Thus, ortho-, meta-and para-tyrosine-chlorambucil analogs were synthesized in order to generate new anticancer drugs with structural diversity, more specifically in regards to the phenol group location. These new analogs were produced in good yield following efficient synthetic methodology. All the tyrosine-chlorambucil hybrids were more effective than the parent drug, chlorambucil. In vitro biological evaluation on estrogen receptor positive and estrogen receptor negative (ER and ER-) breast cancer cell lines revealed an enhanced cytotoxic activity for compounds with the phenol function located at position meta. Molecular docking calculations were performed for the pure L-ortho, L-meta-and L-paratyrosine phenolic regioisomers. The synthesis of all tyrosine-chlorambucil hybrid regioisomers and their biological activity are reported herein. Possible orientations within the targeted protein [estrogen receptor alpha (ERa)] are discussed in relation to the biological activity. Springer-Verlag 2011.

ANTICANCER AGENTS BASED ON AMINO ACID DERIVATIVES

The present invention provides compounds of formula (I): in which T is L or -A-NH-C(O)-L-; L is -(CH2)n- or -(CH2)p-Z-; A is -(CH2)m- or an alkyl component of a naturally occurring amino acid; R is -CO2R1, -CH2OH, -C(O)NH(hydroxyphenyl) or C(S)NH(hydroxyphenyl); R1 is H or is C1-C12 alkyl; X is -OH, OSO2R2, -Cl, -Br, or -I; R2 is C1-C12 alkyl or -CF3; Z is phenyl or naphthyl; m is an integer having a value of 1 to 20; n is an integer having a value of 1 to 20; and p is an integer having a value of 1 to 20 or an enantiomer, diastereoisomer, racemic mixture, pharmaceutically acceptable salt, solvate or prodrug thereof. These compounds can be useful as anticancer agents.

Thiol-based angiotensin-converting enzyme 2 inhibitors: P1′ modifications for the exploration of the S1′ subsite

Explorations of the S1′ subsite of ACE2 via modifications of the P1′ methylene biphenyl moiety of thiol-based metalloprotease inhibitors led to improvements in ACE2 selectivity versus ACE and NEP, while maintaining potent ACE2 inhibi

Synthesis of two novel cyclic biphenyl ether analogs of an inhibitor of HCV NS3 protease

The synthesis of two cyclic ether analogs of a tetrapeptide inhibitor of the hepatitis C virus NS3 protease has been carried out using intramolecular nucleophilic aromatic substitution (S(N)Ar) reactions of ruthenium π-aryl complexes of pre-assembled trip

Peptide sweeteners. 4. Hydroxy and methoxy substitution of the aromatic ring in L-aspartyl-L-phenylalanine methyl ester. Structure-taste relationships.

A series of analogues of the dipeptide sweetener L-aspartyl-L-phenylalanine methyl ester having hydroxy and/or methoxy substitution on the aromatic ring was synthesized and tasted. The introduction of a methoxy group in the para position of the aromatic r